Commentary Article

Diabetic eye disorders and a novel approach via (OPTICORR)

Vinod Chandra Tawar

Vinod Chandra Tawar, et al. Diabetic eye disorders and a novel approach via (OPTICORR). J Endocrine Disorders & Surgery 2021;5(5).

INTRODUCTION: Diabetic eye disorders have been of common occurrence resulting from a progressive uncontrolled disease leading to cataracts and retinopathy. A review of past literature from 2006 to date has demonstrated a common message i.e. utilizations of vitamins for the resolutions of retinal disorders. The researchers in 2006 had shown the effects of retinol as an agent in the treatment of age-related maculopathy.

CASE PRESENTATION: A supplementation in children for Retinal dysfunction. Our current research from 2015 had one primary objective of creating a topical preparation as an alternative to the oral treatment to escape from systemic side effects. The OPTICORR our innovative formulation was studied in the pilot project and had shown a dramatic improvement restoring to normal vision. The patients were instructed to apply OPTICORR

on the eyelids externally for a duration of 12 weeks.

CONCLUSION: The survey responses may be utilized to determine the effectiveness of the Site and the App, various types of communications, advertising campaigns and/or promotional activities. If an Individual participates in a survey, the information given will be used along with that of other study participants. We may share anonymous individual and aggregate data for research and analysis purposes.

Keywords: Endocrine; Drug design; Molecules

Key Words: Neurological Disorder; Endocrinology; Hydrogen bond; Diabetic eye disorders

INTRODUCTION

he researchers in 2006 had shown the effects of retinol as an agent in the treatment of age-related maculopathy. Subsequent studies were focused on Vitamin A supplementation in children for Retinal dysfunction. Our current research from 2015 had one primary objective of creating a topical preparation as an alternative to the oral treatment to escape from systemic side effects. The OPTICORR our innovative formulation was studied in the pilot project and had shown a dramatic improvement restoring to normal vision. The patients were instructed to apply OPTICORR on the eyelids externally for a duration of 12 weeks. A large scale study has been conducted with a target population of 30 patients. The project will be continued for an in determined period due to the encouraging benefits for a duration to normal restoration. In addition, the medication has shown resolution of challenging dermatological diseases. The study was free of any adverse symptoms except for presence of l erythema at the region of the application on the skin would likely indicate intolerance to vitamin ingredients therefore a discontinuation would be warranted, the kinds of information we may collect, how we intend to use and share that information, and how you can correct or change such information ("Privacy Policy"). By using the Scribd.com or the Scribd mobile app, you expressly consent to the information handling practices described in this notice.

Diabetic eye disorders have been of common occurrence resulting from a progressive uncontrolled disease leading to cataracts and retinopathy. A review of past literature from 2006 to date has demonstrated a common message i.e. utilizations of vitamins for the resolutions of retinal disorders. The researchers in 2006 had shown the effects of retinol as an agent in the treatment of agerelated maculopathy. Subsequent studies were focused on Vitamin A supplementation in children for Retinal dysfunction. Our current research from 2015 had one primary objective of creating a topical preparation as an alternative to the oral treatment to escape from systemic side effects. The OPTICORR our innovative formulation was studied in the pilot project and had shown a dramatic improvement restoring to normal vision. The patients were instructed to apply OPTICORR on the eyelids externally for a duration of 12 weeks. A large scale study has been

King George Medical Clinic, Canada.

Correspondence: Vinod Chandra Tawar, King George Medical Clinic, Canada, e-mail: vinodtawar1943@gmail.com Received: October 24, 2021, Accepted: December 02, 2021, Published: December 12, 2021



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License [CC BY-NC] [http://creativecommons.org/licenses/by-nc/4.0/], which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Vinod Chandra Tawar et al.

conducted with a target population of 30 patients. The project will be continued for an in determined period due to the encouraging benefits for duration to normal restoration. In addition, the medication has shown resolution of challenging dermatological diseases. The study was free of any adverse symptoms except for presence of l erythema at the region of the application on the skin would likely indicate intolerance to vitamin ingredients therefore a discontinuation would be warranted.

Scribd and its operating divisions, subsidiaries, affiliates and branches are sensitive to privacy issues, and it is important to us to protect the information provided to us. Accordingly, Scribd provides this privacy and information practices policy to inform you about our online information practices, the kinds of information we may collect, how we intend to use and share that information, and how you can correct or change such information ("Privacy Policy"). By using the Scribd.com or the Scribd mobile app, you expressly consent to the information handling practices described in this notice.

This Privacy Policy applies to Personal Information that is Processed by Scribd in the course of our business, including on the Scribd.com website (the "Site") and the Scribd mobile application (the "App"). All individuals whose responsibilities include the Processing of Personal Information on behalf of Scribd are expected to protect that data by adherence to this Privacy Policy. This Privacy Policy is intended to meet requirements globally, including those in North America, Europe, APAC, and other jurisdictions.

This Privacy Policy is incorporated into and is subject to the General Terms of Use. Your use of Scribd and any Personal Information you provide through Scribd are subject at all times to this Privacy Policy and the General Terms of Use. Terms for "Scribd" apply to any site or mobile application owned and operated by Scribd, Inc.